# US 2021/0032210 A1 · Co-crystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0032210 A1
- Document ID: US20210032210A1
- Status: Published application
- Kind: A1
- Application number: 17/046,120
- Filed: 2019-04-09
- Published: 2021-02-04
- Earliest claimed: 2018-04-11
- Assignees: Letavis AB
- Applicants: Letavis AB
- Inventors: Mihaela Maria POP; Paula VASILICHIA BULIERIS; Ingemar PONGRATZ; Victor FRUTH-OPRISAN; Raul-Augustin MITRAN
- Web page: https://patentgrep.com/patent/US20210032210A1

## CPC

- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 295/027: containing only one hetero ring
- C07C 29/78: by condensation or crystallisation
- C07C 39/21: with at least one hydroxy group on a non-condensed ring
- C07C 49/225: containing six-membered aromatic rings and other rings
- C07C 49/255: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present document is directed to co-crystals of resveratrol and/or curcumin with piperazine and their use in medicine and/or as food and feed supplements.

## Claims

### Claim 1

A resveratrol-piperazine co-crystal, Form 1, characterized by having an XRPD pattern comprising peaks at 4.48, 13.32, 16.96, 18.88, 19.16, and 22.84 °2θ±0.2 °2θ.

### Claim 2 (depends on 1)

The resveratrol-piperazine co-crystal, Form 1, according to claim 1, characterized by having an XRPD pattern according to Table 1.

### Claim 3 (depends on 1, 2)

The resveratrol-piperazine co-crystal, Form 1, according to claim 1 or 2, characterized by having an XRPD pattern as shown in FIG. 1.

### Claim 4

The resveratrol-piperazine co-crystal, Form 1, according to any one of the preceding claims, characterized by having a fusion temperature Tfus of 201° C.±5° C.

### Claim 5

The resveratrol-piperazine co-crystal, Form 1, according to any one of the preceding claims, characterized by having a DSC thermogram as shown in FIG. 2.

### Claim 6

A method for producing the resveratrol-piperazine co-crystal, Form 1, as defined in any one of the preceding claims, said method comprising the steps of:
a) dispensing resveratrol in acetone or acetonitrile;
b) adding piperazine in acetone or acetonitrile to the dispensed resveratrol of step a) thereby providing a resveratrol-piperazine mixture;
c) optionally diluting the resveratrol-piperazine mixture obtained in step b) with acetone or acetonitrile;
d) heating the resveratrol-piperazine mixture obtained in step b) or c) at a temperature within the range of from about 30° C. to about 50° C. under stirring for about 10-30 minutes thereby providing a resveratrol-piperazine suspension;
e) allowing the resveratrol-piperazine suspension obtained in step d) to settle;
f) separating a solid phase obtained in step e); and
g) drying the separated solid phase of step f).

### Claim 7 (depends on 1, 2, 3, 4, 5)

A method for producing the resveratrol-piperazine co-crystal, Form 1, as defined in any one of claims 1-5, said method comprising the steps of:
a) dispensing resveratrol in ethanol;
b) adding piperazine in ethanol to the dispensed resveratrol of step a) thereby providing a resveratrol-piperazine mixture;
c) diluting the resveratrol-piperazine mixture obtained in step b) with ethanol;
d) placing a vessel containing the mixture of step c) within a further vessel containing a solvent such as tert-butyl methyl ether, wherein the mixture of the vessel and the solvent of the further vessel are kept separate from each other;
e) closing the further vessel;
f) allowing the further vessel of step e) to stand for about 7 to about 14 days, such as about 10 days,
g) optionally removing the vessel from the further vessel, and
h) allowing any solvent remaining in the vessel of step f) or step g) to evaporate.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method for producing the resveratrol-piperazine co-crystal, Form 1, as defined in any one of claims 1-5, said method comprising the steps of:
a) subjecting a mixture comprising resveratrol, piperazine and a solvent such as ethanol to grinding such as grinding in a ball mill;
b) allowing the mixture of step a) to dry thereby providing a further mixture; and
c) optionally subjecting the further mixture to further grinding.

### Claim 9 (depends on 1, 2, 3, 4, 5)

A method for producing the resveratrol-piperazine co-crystal, Form 1, as defined in any one of claims 1-5, said method comprising the steps of:
a) adding equimolar amounts of resveratrol and piperazine to a heating device, such as an aluminum pan or hot melt extrusion equipment;
b) heating said resveratrol and said piperazine, such as at a temperature of 100° C. or more, until the resveratrol and piperazine have melted and formed a melted mixture;
c) allowing said melted mixture to cool down.

### Claim 10 (depends on 6, 7, 8, 9)

A resveratrol-piperazine co-crystal, Form 1, obtained or obtainable by the method of any one of claims 6-9.

### Claim 11

A resveratrol-piperazine co-crystal, Form 2, characterized by having an XRPD pattern comprising peaks at 5.87, 12.74, 17.43, 17.70, 20.55, and 21.32 °2θ±0.2 °2θ.

### Claim 12 (depends on 11)

The resveratrol-piperazine co-crystal, Form 2, according to claim 11, characterized by having an XRPD pattern according to Table 2.

### Claim 13 (depends on 11, 12)

The resveratrol-piperazine co-crystal, Form 2, according to claim 11 or 12, characterized by having an XRPD pattern as shown in FIG. 3.

### Claim 14 (depends on 11, 12, 13)

The resveratrol-piperazine co-crystal, Form 2, according to any one of claims 11-13, characterized by having a fusion temperature Tfus of 199° C.±5° C.

### Claim 15 (depends on 11, 12, 13, 14)

The resveratrol-piperazine co-crystal, Form 2, according to any one of claims 11-14, characterized by having a DSC thermogram as shown in FIG. 4.

### Claim 16 (depends on 11, 12, 13, 14, 15)

A method for producing the resveratrol-piperazine co-crystal, Form 2, as defined in any one of claims 11-15, said method comprising the steps of:
a) mixing resveratrol with a solution of piperazine such as a tetrahydrofurane solution of piperazine;
b) adding a further solvent such as tetrahydrofurane to the mixture obtained in step a);
c) placing a vessel containing the solution of step b) within a further vessel containing a solvent such as tert-butyl methyl ether, wherein the solution of the vessel and the solvent of the further vessel are kept separate from each other;
d) closing the further vessel;
e) allowing the further vessel of step d) to stand for about 7 to about 14 days, such as about 10 days;
f) optionally removing the vessel from the further vessel; and
g) allowing any solvent remaining in the vessel of step e) or step f) to evaporate.

### Claim 17 (depends on 11, 12, 13, 14, 15)

A method for producing the resveratrol-piperazine co-crystal, Form 2, as defined in any one of claims 11-15, said method comprising the steps of:
a) subjecting a mixture comprising resveratrol, piperazine and a solvent such as tetrahydrofuran to grinding such as grinding in a ball mill;
b) allowing the mixture of step a) to dry thereby providing a further mixture; and
c) optionally subjecting the further mixture of step b) to further grinding.

### Claim 18 (depends on 16, 17)

A resveratrol-piperazine co-crystal, Form 2, obtained or obtainable by the method of claim 16 or 17.

### Claim 19

A curcumin-piperazine co-crystal, Form 1, characterized by having an XRPD pattern comprising peaks at 4.60, 9.18, 11.31, 13.12, 14.73, 16.97, 22.98, and 24.66 °2θ±0.2 °2θ.

### Claim 20 (depends on 19)

The curcumin-piperazine co-crystal, Form 1, according to claim 19, characterized by having an XRPD pattern according to Table 3.

### Claim 21 (depends on 19, 20)

The curcumin-piperazine co-crystal, Form 1, according to claim 19 or 20, characterized by having an XRPD pattern as shown in FIG. 5.

### Claim 22 (depends on 19, 20, 21)

The curcumin-piperazine co-crystal, Form 1, according to any one of claims 19-21, characterized by having a fusion temperature Tfus of 94° C.±5° C.

### Claim 23 (depends on 19, 20, 21, 22)

The curcumin-piperazine co-crystal, Form 1, according to any one of claims 19-22, characterized by having a DSC thermogram as shown in FIG. 6.

### Claim 24 (depends on 19, 20, 21, 22, 23)

A method for producing the curcumin-piperazine co-crystal, Form 1, as defined in any one of claims 19-23, said method comprising the steps of:
a) mixing:
(i) a solution of curcumin, such as an acetonitrile solution of curcumin, and
(ii) a solution of piperazine, such as an acetonitrile solution of piperazine;
b) stirring the mixture obtained in step a) at a temperature within the range of from about 40° C. to about 80° C., such as about 60° C., for a time of about 1 minute to about 60 minutes, such as 5 minutes;
c) allowing the mixture obtained in step b) to settle thereby providing a solid phase and a liquid phase;
d) separating the solid phase from the liquid phase; and
e) drying the solid phase.

### Claim 25 (depends on 24)

A curcumin-piperazine co-crystal, Form 1, obtained or obtainable by the method of claim 24.

### Claim 26

A curcumin-piperazine co-crystal, Form 2, characterized by having an XRPD pattern comprising peaks at 4.93, 9.46, 9.85, 13.98, 17.77, and 21.48 °2θ±0.2 °2θ.

### Claim 27 (depends on 26)

The curcumin-piperazine co-crystal, Form 2, according to claim 26, characterized by having an XRPD pattern according to Table 4.

### Claim 28 (depends on 26, 27)

The curcumin-piperazine co-crystal, Form 2, according to claim 26 and 27, characterized by having an XRPD pattern as shown in FIG. 7.

### Claim 29 (depends on 26, 27, 28)

The curcumin-piperazine co-crystal, Form 2, according to any one of claims 26-28, characterized by having a fusion temperature Tfus of 87° C.±5° C.

### Claim 30 (depends on 26, 27, 28, 29)

The curcumin-piperazine co-crystal, Form 2, according to any one of claims 26-29, characterized by having a DSC thermogram as shown in FIG. 8.

### Claim 31 (depends on 26, 27, 28, 29, 30)

A method for producing the curcumin-piperazine co-crystal, Form 2, as defined in any one of claims 26-30, said method comprising the steps of:
a) mixing:
(i) a solution of curcumin, such as a tetrahydrofurane solution of curcumin, and
(ii) a solution of piperazine, such as a tetrahydrofurane;
b) placing a vessel containing the mixture obtained in step a) within a further vessel containing a solvent such as hexane, wherein the mixture of the vessel and the solvent of said further vessel are kept separate from each other;
c) closing the further vessel;
d) allowing the further vessel of step c) to stand for about 7 to about 14 days such as 10 days;
e) optionally removing the vessel from the further vessel; and
f) allowing any solvent remaining in the vessel of step d) or step e) to evaporate.

### Claim 32 (depends on 26, 27, 28, 29, 30)

A method for producing the curcumin-piperazine co-crystal, Form 2, as defined in any one of claims 26-30, said method comprising the steps of:
a) subjecting a mixture of curcumin, piperazine and a solvent such as tetrahydrofuran to grinding such as grinding in a ball mill;
b) allowing the mixture of step a) to dry thereby providing a further mixture; and
c) optionally subjecting the further mixture of step b) to further grinding.

### Claim 33 (depends on 31, 32)

A curcumin-piperazine co-crystal, Form 2, obtained or obtainable by the method of claim 31 or 32.

### Claim 34

A resveratrol-piperazine-curcumin co-crystal characterized by having an XRPD pattern comprising peaks at 4.26, 11.86, 16.78, 23.46, and 25.68 °2θ±0.2 °2θ.

### Claim 35 (depends on 34)

The resveratrol-piperazine-curcumin co-crystal according to claim 34, characterized by having an XRPD pattern according to Table 5.

### Claim 36 (depends on 34, 35)

The resveratrol-piperazine-curcumin according to claim 34 or 35, characterized by having an XRPD pattern as shown in FIG. 9.

### Claim 37 (depends on 34, 35, 36)

The resveratrol-piperazine-curcumin according to any one of claims 34-36, characterized by having a fusion temperature Tfus of 105° C.±5° C.

### Claim 38 (depends on 34, 35, 36, 37)

The resveratrol-piperazine-curcumin according to any one of claims 34-37, characterized by having a DSC thermogram as shown in FIG. 10.

### Claim 39 (depends on 34, 35, 36, 37, 38)

A method for producing the resveratrol-piperazine-curcumin co-crystal, as defined in any one of claims 34-38, said method comprising the steps of:
a) mixing:
(i) a solution of curcumin, such as an acetone solution of curcumin, and
(ii) a solution of resveratrol, such as an acetone solution of resveratrol, optionally under stirring;
b) adding a solution of piperazine, such as an acetone solution of piperazine, to the mixture obtained in step a), optionally under stirring;
c) placing a vessel containing the mixture obtained in step b) within a further vessel containing a solvent such as hexane, wherein the mixture of the vessel and the solvent of the further vessel are kept separate from each other;
d) closing the further vessel;
e) allowing the further vessel of step d) for about 7 to about 14 days, such as about 10 days;
f) optionally removing the vessel from the further vessel; and
g) allowing any solvent remaining in the vessel of step e) or step f) to evaporate.

### Claim 40 (depends on 39)

A resveratrol-piperazine-curcumin co-crystal, obtained or obtainable by the method of claim 39.

### Claim 41 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A composition, such as a health supplement, food or feed composition, or a food or feed additive, comprising a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40.

### Claim 42 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use as a medicament.

### Claim 43 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 34, 35, 36, 37, 38, 40)

A resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use in the treatment and/or prevention of skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy and/or inflammation.

### Claim 44 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for the preparation of a medicament for the treatment and/or prevention of skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy and/or inflammation.

### Claim 45 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 34, 35, 36, 37, 38, 40)

A method for treating and/or preventing skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy and/or inflammation comprising administering a pharmaceutically acceptable amount of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 to a subject in need thereof.

### Claim 46 (depends on 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use in the treatment and/or prevention of osteoarthritis, prostate cancer, colon cancer, skin cancer, breast cancer, arteriosclerosis, digestive problems, ulcerative colitis, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, dementia and/or metabolic syndrome.

### Claim 47 (depends on 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30, 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for the preparation of a medicament for the treatment and/or prevention of osteoarthritis, prostate cancer, colon cancer, skin cancer, breast cancer, arteriosclerosis, digestive problems, ulcerative colitis, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, dementia and/or metabolic syndrome.

### Claim 48 (depends on 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A method for treating and/or preventing osteoarthritis, prostate cancer, colon cancer, skin cancer, breast cancer, arteriosclerosis, digestive problems, ulcerative colitis, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, dementia and/or metabolic syndrome comprising administering a pharmaceutically acceptable amount of a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30, 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 to a subject in need thereof.

### Claim 49 (depends on 34, 35, 36, 37, 38, 40)

A resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use in the treatment and/or prevention of skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy, inflammation, osteoarthritis, arteriosclerosis, digestive problems, dementia and/or metabolic syndrome.

### Claim 50 (depends on 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for the preparation of a medicament for the treatment and/or prevention of skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy, inflammation, osteoarthritis, arteriosclerosis, digestive problems, dementia and/or metabolic syndrome.

### Claim 51 (depends on 34, 35, 36, 37, 38, 40)

A method for treating and/or preventing skin cancer, prostate cancer, colon cancer, lung cancer, breast cancer, liver cancer, heart disease, arteriosclerosis, hypertension, type II diabetes, metabolic syndrome, Alzheimer's disease, Crohn's Disease, Inflammatory Bowel Disease, autoimmune inflammatory diseases, mental disorder, ulcerative colitis, ileitis, porcine enteropathy, proliferative haemorrhagic enteropathy, inflammation, osteoarthritis, arteriosclerosis, digestive problems, dementia and/or metabolic syndrome comprising administering a pharmaceutically acceptable amount of a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40, to a subject in need thereof.

### Claim 52 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use in the treatment and/or prevention of ileitis and/or a bacterial infection, such as in live-stock, such as swine and/or poultry.

### Claim 53 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for the preparation of a medicament for the treatment and/or prevention of ileitis and/or a bacterial infection, such as in live-stock, such as swine and/or poultry.

### Claim 54 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A method for treating and/or preventing ileitis and/or a bacterial infection, such as in live-stock, such as swine and/or poultry, comprising administering a pharmaceutically acceptable amount of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 to a subject in need thereof.

### Claim 55 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 as a food or feed supplement and/or a food or feed additive.

### Claim 56 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for increasing the growth of live-stock, such as swine and/or poultry.

### Claim 57 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for stabilizing a microbial flora, such as a gut microbial flora.

### Claim 58 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for treating and/or preventing weaning problems, such as weaning problems in live-stock, such as in swine and/or poultry.

### Claim 59 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for use in the treatment and/or prevention weaning problems, such as weaning problems in live-stock, such as in swine and/or poultry.

### Claim 60 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

Use of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 for the preparation of a medicament for the treatment and/or prevention of weaning problems, such as weaning problems in live-stock, such as in swine and/or poultry.

### Claim 61 (depends on 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 40)

A method for treating and/or preventing weaning problems, such as weaning problems in live-stock, such as in swine and/or poultry, comprising administering a pharmaceutically acceptable amount of a resveratrol-piperazine co-crystal as defined in any one of claims 1-5, 10-15 and 18, a curcumin-piperazine co-crystal as defined in any one of claims 19-23, 25-30 and 33 and/or a resveratrol-piperazine-curcumin co-crystal as defined in any one of claims 34-38 and 40 to a subject in need thereof.
